New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 31, 2014
11:18 EDTACT, ENDPEndo Health wins appeal ruling over Actavis related to Opana ER
A federal appeals court ruled that a district court erred in concluding that Roxane and Actavis (ACT) had an implied license to practice asserted patents related to Opana ER, which is sold in branded form by Endo Health (ENDP). The appeals court vacated the lower court ruling and remanded the suit for further judgment. Reference Link
News For ENDP;ACT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 26, 2015
17:34 EDTACTActavis registration statement for Allergan acquisition declared effective
Subscribe for More Information
07:34 EDTACTActavis to acquire Auden Mckenzie for GBP306M accretive in FY15
Subscribe for More Information
January 22, 2015
14:03 EDTENDPAuxilium to host special shareholder meeting
Subscribe for More Information
05:57 EDTACTActavis, Valeant raise prospects of more healthcare deals, Financial Times says
Subscribe for More Information
January 21, 2015
18:27 EDTENDPOn The Fly: After Hours Movers
UP AFTER EARNINGS: eBay (EBAY), up 2.9%... United Rentals (URI), up 1.5%. ALSO HIGHER: Minerva (NERV), up 16.1% after reporting positive Phase 1 data with MIN-202... Endo (ENDP), up 3.1% after it was announced that Endo will replace Covidien in S&P 500 as of 1/26 close... Covidien (COV) is up 1%. DOWN AFTER EARNINGS: F5 Networks (FFIV), down 15.8%... Xilinx (XLNX), down 6.1%... Discover Financial Services (DFS), down 3.3%... American Express (AXP), down 2.2%. ALSO LOWER: BioMarin (BMRN), down 2.5% after filing to sell 7.25M shares of common stock... Kinder Morgan (KMI), down 1.9% after announcing that it will acquire Hiland Partners for approximately $3B and reporting fourth quarter results... Cisco (CSCO), down 1.4% after Bloomberg reported that Oracle's (ORCL) Ellison said that Oracle's new Virtual Compute Appliance is cheaper than Cisco's product.
18:06 EDTENDPS&P announces changes to the S&P 500, MidCap 400, SmallCap 600 indices
Subscribe for More Information
17:19 EDTENDPBoston Beer to replace Endo in S&P 400 as of 1/26 close
Subscribe for More Information
17:18 EDTENDPEndo to replace Covidien in S&P 500 as of 1/26 close
12:30 EDTACTGlaxoSmithKline 'admired' by Pfizer CEO, FT reports
Subscribe for More Information
07:22 EDTACTActavis price target raised to $330 from $280 at Deutsche Bank
Subscribe for More Information
January 20, 2015
07:00 EDTENDPEndo price target raised to $98 from $86 at Piper Jaffray
Piper Jaffray raised its price target for Endo shares to $98 saying Xiaflex's market expansion opportunities are not fully appreciated by the broader market. It keeps an Overweight rating on the stock.
05:34 EDTACTActavis reports positive Phase III results for cariprazine
Gedeon Richter and Actavis announced positive results from a Phase III trial evaluating the efficacy and safety of cariprazine in the prevention of relapse in patients with schizophrenia. There were 101 patients randomized to cariprazine 3 to 9 mg per day and 99 randomized to placebo. The primary efficacy measure was time to first relapse during the double-blind period. There were 25 relapses in the cariprazine group versus 47 relapses in the placebo group. Treatment with cariprazine was associated with a 55% reduction in risk of relapse versus placebo.
January 14, 2015
18:18 EDTACTOn The Fly: After Hours Movers
Subscribe for More Information
16:59 EDTACTGalena, Orexo AB receive "Paragraph IV" patent certification notice from Actavis
Subscribe for More Information
January 13, 2015
14:00 EDTACTActavis says Allergan deal could close as early as Q1, as late as Q2
Subscribe for More Information
13:49 EDTACTActavis says sees about $8B in free cash flow in 2016
Subscribe for More Information
13:42 EDTACTActavis targeting 2017 EPS of $25
Subscribe for More Information
13:38 EDTACTActavis sees Q4 adjusted EPS beating consensus by 10%-15%
Subscribe for More Information
08:05 EDTACTActavis launches US generic specialty injectable portfolio
Actavis announced the launch of a portfolio of generic specialty injectable medications to be marketed to hospitals across the United States. Actavis will immediately begin marketing approximately 20 injectable products across a number of therapeutic categories in the U.S. The company hopes to be a leader in Oncology, with nearly a dozen marketed products including generic versions of Gemzar, Taxotere, Campostar and Zometa. Actavis also has an industry leading specialty injectable pipeline, with approximately 20 new filings under review at the U.S. Food and Drug Administration, as well as more than 50 additional projects currently in development.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use